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ABSTRACT
Introduction: In a previous pooled analysis of
19 double-blind clinical studies conducted by
Merck, which included data available as of July
2009 on 10,246 patients with type 2 diabetes
(T2DM), treatment with sitagliptin was shown
to be generally well tolerated compared with
treatment with control agents. As the sitagliptin
clinical development program continues,
additional studies with sitagliptin have been
completed. The present analysis updates the
safety and tolerability assessment of sitagliptin
by examining pooled data from 25 double-blind
clinical studies.
Methods: The present analysis included data
from 14,611 patients in 25 studies with T2DM
who received either sitagliptin 100 mg/day
(n = 7,726; sitagliptin group) or a comparator
agent (n = 6,885; non-exposed group). These
studies represent all randomized, double-blind
trials conducted by Merck that included
patients treated with the usual clinical dose of
sitagliptin (100 mg/day) for between 12 weeks
and 2 years, and for which results were available
as of December 2011. These studies assessed
sitagliptin, versus comparator agents, taken as
monotherapy, initial combination therapy with
metformin or pioglitazone, or as add-on
combination therapy with other
antihyperglycemic agents (metformin,
pioglitazone, a sulfonylurea ± metformin,
insulin ± metformin, or
metformin ? pioglitazone or rosiglitazone).
Patient-level data from each study were used
to evaluate between-group differences in the
exposure-adjusted incidence rates of adverse
events (AEs).
Results: Overall incidence rates of AEs and
drug-related AEs were higher in the non-
exposed group compared with the sitagliptin
group. Incidence rates of specific AEs were
generally similar between the two groups,
except for higher incidence rates of
hypoglycemia related to the greater use of a
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sulfonylurea and diarrhea related to the greater
use of metformin in the non-exposed group,
and of constipation in the sitagliptin group.
Treatment with sitagliptin was not associated
with an increased risk of major adverse
cardiovascular events, malignancy, or
pancreatitis.
Conclusion: In this updated pooled safety
analysis of data from 14,611 patients with
T2DM, sitagliptin 100 mg/day was generally
well tolerated in clinical trials of up to 2 years
in duration.
Keywords: Adverse events; Dipeptidyl
peptidase-4 inhibitor; Safety; Sitagliptin;
Tolerability; Type 2 diabetes
INTRODUCTION
Since the introduction of sitagliptin into the
diabetes therapeutic armamentarium in 2006,
the use of dipeptidyl peptidase-4 (DPP-4)
inhibitors for the management of
hyperglycemia in patients with type 2 diabetes
has increased worldwide. The role of DPP-4
inhibitors in diabetes treatment guidelines has
similarly evolved, with the most recent
American Diabetes Association (ADA)/
European Association for the Study of Diabetes
(EASD) consensus guidelines considering DPP-4
inhibitors to be an appropriate second-line
therapy after the initiation of metformin, and
in the same category as other available
antihyperglycemic therapies (including
sulfonylureas, thiazolidinediones, glucagon-
like peptide-1 (GLP-1) receptor agonists, and
insulin) [1]. This represented a distinct
departure from prior ADA/EASD guidelines,
which considered only sulfonylureas and
insulin to be ‘‘well-validated’’ second-line
agents [2]. The emergence of the DPP-4
inhibitors has been driven in large part by the
safety and tolerability profile of this class of
agents compared with other antihyperglycemic
agents. In particular, the low risk of
hypoglycemia, the weight-neutrality, and the
generally excellent tolerability when compared
with other classes of drugs appear to have
distinguished this class of incretin-based
therapies.
In that context, it is important to continue
to evaluate the safety and tolerability of this
newer class of antihyperglycemic therapy in
well-designed, randomized, controlled clinical
trials. Recently, Monami et al. [3] performed an
updated meta-analysis of 53 trials of at least
24 weeks in duration, which included over
33,000 patients with type 2 diabetes. In this
analysis, which comprised 20,312 patients
treated with a DPP-4 inhibitor and 13,569
patients treated with either placebo or an
active comparator, outcomes of interest
included the incidences of cancer, pancreatitis,
all-cause and cardiovascular mortality, and
major adverse cardiovascular events (MACE).
There was no evidence of an increase in the
incidence of cancer [Mantel–Haenszel odds
ratio (MH-OR) 1.020, 95% CI 0.742, 1.402] or
pancreatitis (MH-OR 0.786, 95% CI 0.357,
1.734) with DPP-4 inhibitor therapy. The
overall MH-OR for all-cause and cardiovascular
death in patients treated with DPP-4 inhibitor
was 0.668 (95% CI 0.396, 1.124) and 0.505 (95%
CI 0.252, 1.011), respectively. Additionally, a
significantly lower risk of MACE (MH-OR 0.689,
95% CI 0.528, 0.899) was observed. While meta-
analyses of published studies can provide an
assessment of large numbers of patients across
the class of DPP-4 inhibitors, the absence of
patient-level data for specific adverse events and
the focus, in most publications, on serious
adverse experiences limit the ability of such
analyses to provide a comprehensive assessment
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of the overall safety and tolerability profile of an
individual DPP-4 inhibitor.
As part of the assessment of the safety and
tolerability profile of sitagliptin, pooled
analyses of patient-level clinical trial data have
been previously reported [4–6]. This current
pooled analysis includes data from 25 double-
blind, randomized studies of sitagliptin 100 mg/
day, and incorporates approximately 40% more
patients and approximately 36% more patient-
years of exposure than the prior pooled analysis.
The availability of patient-level data coupled
with a larger patient exposure allow for an
enhanced ability to assess the incidence of less
common adverse experiences, and also allow for
more precise estimates of the incidence rates of
reported adverse experiences.
METHODS
This post hoc analysis used a pooled population
(n = 14,611) drawn from all 25 multicenter, US
or multinational, double-blind, parallel-group
studies conducted by Merck & Co., Inc., in
which patients were randomized to receive
sitagliptin 100 mg/day (n = 7,726) or a
comparator (n = 6,885) for at least 12 weeks
and up to 2 years (the duration of the longest
studies) and for which results were available as
of December 1, 2011 (complete study listing in
Table 6 in Appendix). Each protocol was
reviewed and approved by appropriate ethical
review committees and authorities for each
clinical site. All patients were to have provided
written informed consent. The studies
evaluated sitagliptin as monotherapy, initial
combination therapy with either metformin or
pioglitazone, or add-on combination therapy
with other antihyperglycemic agents, including
metformin, pioglitazone, a sulfonylurea (with
and without metformin), insulin (with and
without metformin), or metformin with
rosiglitazone or pioglitazone. Patients not
receiving sitagliptin (i.e., the non-exposed
group) received placebo, metformin,
pioglitazone, a sulfonylurea (with and without
metformin), insulin (with and without
metformin), or metformin with rosiglitazone
or pioglitazone. From each contributing study,
the pooling was conducted by including those
portions of each study that had parallel
treatment groups with concurrent exposures to
sitagliptin 100 mg/day (primarily administered
as 100 mg once daily) or other treatments
(either placebo or active comparator). Studies
conducted only in Japan were excluded from all
analyses; a lower starting dose of sitagliptin has
been separately developed in Japan. The
pooling excluded studies conducted in
patients with moderate-to-severe renal
insufficiency, because these patients received
sitagliptin at doses less than 100 mg/day.
Studies describing the safety and tolerability of
sitagliptin in patients with moderate and severe
renal insufficiency have been previously
published [7–9].
In each study, investigators were to report
adverse events (serious and non-serious) that
occurred during the conduct of the study, as
well as serious adverse events occurring within
14 days following the last dose of blinded study
drug. These events were encoded in a uniform
manner using the Medical Dictionary for
Regulatory Activities (MedDRA version 14.1;
MedDRA MSSO, Chantilly, VA, USA), in which
terms for specific adverse events that are alike or
pertain to the same organ system are
categorized by System Organ Class (SOC). To
account for potential differences between
groups in duration of exposure to treatment,
reports of adverse events are expressed as
exposure-adjusted incidence rates (numbers of
patients with events per 100 patient-years).
These analyses were based on the time to the
Diabetes Ther (2013) 4:119–145 121
123
first (incident) event, calculated as follows:
incident event rate = 100 9 (total number of
patients with C1 event during eligible exposure
period per total patient-years of exposure). The
incident event rate per 100 patient-years is
referred to as the ‘‘incidence rate’’ throughout
the manuscript. For those patients for whom an
event was reported, the patient-years of
exposure were calculated as the time from the
first dose of sitagliptin (or comparator) at
randomization to the time that the first post-
randomization event occurred. For patients
without an event, the patient-years of
exposure were calculated as the time from the
first dose to 14 days after the last dose of study
medication (i.e., sitagliptin or comparator).
Differences between treatment groups and the
associated 95% CI were calculated using the
Miettinen and Nurminen method, stratified by
study [10]. For endpoints occurring in fewer
than four patients in both groups, 95% CIs were
not computed because they did not have the
potential of excluding zero. No statistical
adjustments were performed for multiple
comparisons. All analyses were performed
using SAS version 9.1; SAS Institute, Inc.,
Cary, NC, USA.
The present analysis used patient-level data
from each study to assess the incidence rates of
adverse events that occurred following
initiation of double-blind study drug. Many
studies in this analysis included open-label
glycemic rescue therapy, which was to have
been initiated based on protocol-specified
hyperglycemia criteria that were progressively
stricter over the course of the study. When
initiated, glycemic rescue therapy was added to
the ongoing, blinded study medication to
which patients had been randomized. Except
where mentioned otherwise, the analyses
presented below include all post-
randomization events reported to have
occurred during a given study, including those
events with onset after the initiation of
glycemic rescue therapy.
The analysis in this article is based on
previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
Adverse Events of Interest
Hypoglycemia
For most studies, hypoglycemia was
prespecified as an adverse event of interest. For
all of the trials that were pooled for this
analysis, hypoglycemia was based on
investigator interpretation of clinical
symptoms, without the requirement for a
concurrent glucose determination. In contrast
to the general analysis of adverse events,
analyses of hypoglycemia adverse events
excluded data following initiation of glycemic
rescue therapy to avoid the confounding
influence of medications that could cause
hypoglycemia. In addition, a separate pooled
analysis was performed including only those
studies and portions of studies that did not
include a sulfonylurea or insulin, to
characterize the rate of hypoglycemia with
sitagliptin relative to comparators not
generally associated with an increased risk for
hypoglycemia (i.e., metformin and
pioglitazone, as well as placebo).
Gastrointestinal
The incidence of a composite endpoint of
gastrointestinal (GI) adverse events (including
diarrhea, nausea, vomiting, constipation, and a
composite abdominal pain term, which
included abdominal pain, upper and lower
abdominal pain, abdominal and epigastric
discomfort, and GI pain) was calculated. An
additional analysis of these GI endpoints was
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conducted, excluding studies and portions of
studies in which patients initiated metformin,
to characterize the rate of these GI events with
sitagliptin relative to comparators generally not
associated with an increased risk for GI events.
This separate analysis excluded data following
initiation of glycemic rescue therapy.
MACE
An analysis of adverse cardiovascular events
comprised of cardiovascular death in addition
to ischemic events considered to be MACE was
performed. For the MACE-related analysis, an
exact method for Poisson processes [11],
stratified by study, was used to calculate the
exposure-adjusted incidence rate ratios
(sitagliptin relative to comparator) and the
associated 95% CI.
Neoplasms
All adverse event terms for neoplasms were
reviewed in a blinded fashion and classified as
corresponding to malignant or non-malignant
neoplasms. All terms for malignant neoplasms
were contained within the ‘‘Neoplasms benign,
malignant, and unspecified’’ SOC, whereas
terms for non-malignant neoplasms were
contained both within and outside of the
‘‘Neoplasms benign, malignant, and
unspecified’’ SOC. Incidence rates and
between-group differences were computed for
individual neoplasms as well as for the
composite endpoints of all malignant
neoplasms, all non-malignant neoplasms in
the ‘‘Neoplasms benign, malignant, and
unspecified’’ SOC, and all non-malignant
neoplasms regardless of SOC.
Angioedema
Angioedema events and angioedema-related
events, based on an expanded version of the
Standard MedDRA Query (SMQ) that included
anaphylactic reactions and hypersensitivity,
were summarized by treatment group for the
periods with and without exposure to an
angiotensin-converting enzyme (ACE)
inhibitor. Exposure to an ACE inhibitor was
defined as the total days of use of an ACE
inhibitor during the double-blind treatment
period, with patients contributing to patient-
years of exposure to an ACE inhibitor for the
actual period of time that they were reported to
have been taking an ACE inhibitor and to
patient-years of non-exposure for the actual
period of time that they were reported not to
have been taking an ACE inhibitor.
Composite Endpoints of Interest
Incidence rates and between-group differences
were calculated for a variety of composite
endpoints, consisting of a collection of
MedDRA adverse event terms related to the
safety issue of interest. These composite
endpoints included pancreatitis, pancreatic
cancer, acute renal failure, proteinuria,
bronchitis, pneumonia, upper respiratory
infection, urinary tract infection, atrial
fibrillation/flutter, and rash.
Laboratory Abnormalities
Percentages of patients meeting predefined
laboratory abnormality criteria for liver
enzyme abnormalities [alanine
aminotransferase (ALT) and aspartate
aminotransferase (AST)] and for serum
creatinine were compared between groups.
RESULTS
Patient Characteristics and Exposure
In the entire 25-study cohort, patients (55%
male) had an mean age of 54 years (range
19–91 years; 17% C65 years), a mean duration
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of diabetes of 5.1 years, and a mean glycosylated
hemoglobin (HbA1c) of 8.4% at baseline (with
29% of patients having a baseline HbA1c
C9.0%) (Table 1). The majority of patients
were White (61%), with 18% Asian and 6%
Black. At baseline, 10% of patients had a history
of cardiovascular disease, and 81% had
additional cardiovascular risk factors besides
type 2 diabetes mellitus and cardiovascular
disease, including hypertension (53%), history
of dyslipidemia/hypercholesterolemia (49%),
and history of smoking (39%). There were no
meaningful differences between groups in these
baseline characteristics.
The mean exposure to study drug was
slightly greater in the sitagliptin group relative
to the non-exposed group: 284 dosing days
(range 1–791) and 264 dosing days (range








Male 4,196 (54) 3,788 (55) 7,984 (54.6)
Age, years 54.0 ± 10.3 54.4 ± 10.5 54.2 ± 10.4
Race, n (%)
White 4,674 (60) 4,227 (61) 8,901 (61)
Black 427 (6) 384 (6) 811 (6)
Asian 1,436 (19) 1,227 (18) 2,663 (18)
Multiracial 462 (6) 427 (6) 889 (6)
Other or unknown 727 (9) 620 (9) 1,347 (9)
Body weight, kg 85.0 ± 19.6 85.8 ± 20.1 85.3 ± 19.8
Body mass index, kg/m2 30.5 ± 5.7 30.7 ± 5.8 30.6 ± 5.7
HbA1c, % 8.4 ± 1.3 8.4 ± 1.3 8.4 ± 1.3
Duration of T2DMa, years 5.1 ± 5.4 5.1 ± 5.3 5.1 ± 5.4
On antihyperglycemic therapy, n (%) 3,001 (38.8) 2,773 (40.3) 5,774 (39.5)
History of CVD, n (%) 793 (10) 691 (10) 1,484 (10)
Patients with known CV risk factors other
than T2DM and history of CVD, n (%)b
5,828 (81) 5,269 (82) 11,097 (81)
History of dyslipidemia, n (%) 3,862 (50) 3,356 (49) 7,218 (49)
History of hypertension, n (%) 4,110 (53) 3,666 (53) 7,776 (53)
History of smoking, n (%)b 2,712 (38) 2,539 (39) 5,251 (39)
Data are expressed as mean (± standard deviation) or frequency [n (%)], unless otherwise indicated
CV cardiovascular, CVD cardiovascular disease, HbA1c glycosylated hemoglobin, T2DM type 2 diabetes mellitus
a Excludes 16 patients (11 sitagliptin, 5 non-exposed) with unknown duration of diabetes
b Denominator is 7,177 for sitagliptin group and 6,451 for non-exposed group because history of smoking was not collected
in all patients from Protocols 010, 014 and 074, and 11 patients from other studies did not provide information on smoking
history
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1–801), respectively. In the sitagliptin group,
2,457 (32%) patients were treated for at least
1 year, with 584 (8%) of these patients treated
for 2 years; the corresponding numbers of
patients in the non-exposed group were 1,775
(26%) and 470 (7%). The proportions of
patients discontinuing treatment were 27.2%
in the sitagliptin group and 28.8% in the non-
exposed group.
Summary Measures of Adverse Events
The incidence rate of patients reporting one or
more adverse events was higher in the non-
exposed group compared with the sitagliptin
group (Table 2). The incidence rate of drug-
related adverse events was also higher in the
non-exposed group, as was the incidence of
patient discontinuations due to a drug-related
adverse event; this was primarily due to the
greater incidence rate of adverse events of drug-
related hypoglycemia reported for the non-
exposed group (data not shown). The
incidence of serious adverse events was similar
for the two groups, both overall (Table 2) and by
SOC category (data not shown). The incidence
of adverse events resulting in death, overall, was
similar in the two treatment groups; for the
Neoplasms SOC, however, the incidence of
adverse events resulting in death was lower in
the sitagliptin group compared with the non-
exposed group (one event in 6,388 patient-years
of follow-up compared with six events in 5,378
patient-years of follow-up, respectively, with a
difference in rates of -0.1 events per
100-patient-years (95% CI -0.2, -0.0).
Incidence rates for adverse events in each SOC
are in Table 3. There were three SOCs
(Metabolism and nutrition disorders;
Neoplasms benign, malignant, and unspecified;
and Skin and subcutaneous tissue disorders) for
which the 95% CI for the between-group
Table 2 Adverse event summary
Incidence rate per 100 patient-yearsa
Sitagliptin Non-exposed Difference between
sitagliptin and
non-exposed (95% CI)b
C1 adverse events 142.8 151.1 -7.6 (-13.9, -1.3)
With one or more drug-relatedc adverse events 19.1 25.5 -5.9 (-7.8, -4.1)
With one or more serious adverse events 7.3 6.9 0.4 (-0.6, 1.4)
With one or more serious drug-relatedc adverse events 0.4 0.2 0.1 (-0.1, 0.4)
Deaths 0.3 0.4 -0.1 (-0.4, 0.1)
Discontinuations due to adverse events 4.5 4.9 -0.5 (-1.3, 0.3)
Discontinuations due to drug-relatedc adverse event 1.6 2.2 -0.5 (-1.0, -0.0)
Discontinuations due to serious adverse event 1.7 1.4 0.2 (-0.2, 0.7)
Discontinuations due to serious drug-relatedc adverse event 0.2 0.1 0.1 (-0.0, 0.3)
a 100 9 (number of patients with C1 event/patient-years of follow-up time)
b Between-group difference and 95% CI based on stratiﬁed analysis. Positive differences indicate that the incidence rate for
the sitagliptin group is higher than the incidence rate for the non-exposed group. ‘‘-0.0’’ represents rounding of values that
were slightly less than zero
c As determined by the investigator
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difference in incidence rates excluded 0. The
between-group difference in the incidence rates
of adverse events in the Metabolism and
nutrition disorders SOC was primarily due to a
higher incidence rate of hypoglycemia in the
non-exposed group. The between-group
difference in the Neoplasms benign, malignant,
and unspecified SOC was related to a higher
incidence rate in the sitagliptin group for non-
malignant adverse events within the Neoplasms
benign, malignant, and unspecified SOC, and
was not the result of an imbalance in any single
adverse event or any group of biologically related
adverse events. The incidence rates of
malignancy were similar for the two groups:
0.90 per 100 patient-years in the sitagliptin group
and 0.93 per 100 patient-years in the non-
exposed group [between-group difference of
Table 3 Summary of adverse event system organ classes






Blood and lymphatic system disorders 1.2 0.9 0.2 (-0.1, 0.6)
Cardiac disorders 3.7 3.8 -0.2 (-0.9, 0.5)
Congenital, familial, and genetic disorders 0.2 0.2 -0.0 (-0.2, 0.1)
Ear and labyrinth disorders 1.6 1.9 -0.4 (-0.9, 0.1)
Endocrine disorders 0.3 0.4 -0.2 (-0.4, 0.0)
Eye disorders 3.8 3.9 -0.1 (-0.9, 0.6)
Gastrointestinal disorders 24.3 24.6 0.3 (-1.7, 2.3)
General disorders and administration site conditions 8.3 9.2 -0.9 (-2.1, 0.2)
Hepatobiliary disorders 1.2 0.9 0.2 (-0.1, 0.6)
Immune system disorders 0.9 0.9 -0.1 (-0.4, 0.3)
Infections and infestations 45.5 45.7 0.3 (-2.5, 3.1)
Injury, poisoning and procedural complications 8.8 8.8 0.3 (-0.9, 1.4)
Investigations 14.0 14.9 -1.3 (-2.7, 0.2)
Metabolism and nutrition disorders 11.1 17.5 -6.4 (-7.9, -4.9)
Musculoskeletal and connective tissue disorders 19.3 18.5 0.7 (-1.0, 2.4)
Neoplasms benign, malignant and unspeciﬁed 2.0 1.5 0.6 (-0.0, 1.2)
Nervous system disorders 15.1 14.7 0.3 (-1.1, 1.8)
Pregnancy, puerperium, and perinatal conditions 0.0 0.1 -0.0 (-0.1, 0.1)
Psychiatric disorders 4.3 4.5 -0.1 (-0.9, 0.6)
Renal and urinary disorders 2.8 2.6 0.1 (-0.5, 0.7)
Reproductive system and breast disorders 2.6 2.8 -0.2 (-0.8, 0.4)
Respiratory, thoracic and mediastinal disorders 7.9 8.0 -0.1 (-1.2, 0.9)
Skin and subcutaneous tissue disorders 7.8 6.7 1.1 (0.1, 2.1)
Social circumstances 0.0 0.0 -0.0c
Surgical and medical procedures 0.0 0.0 0.0c
Vascular disorders 5.4 5.3 -0.1 (-1.0, 0.7)
SOC system organ class
a 100 9 (number of patients with C1 event in the SOC/patient-years of follow-up time)
b Between-group difference and 95% CI based on stratiﬁed analysis. Positive differences indicate that the incidence rate for the sitagliptin
group is higher than the incidence rate for the non-exposed group. ‘‘0.0’’ and ‘‘-0.0’’ represent rounding for values that are slightly greater
and slightly less than zero, respectively
c 95% CI were not computed for events that occurred in fewer than four patients in both groups, because the CI would necessarily have
included 0
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-0.05 (95% CI -0.41, 0.30)]. For the Skin and
subcutaneous disorders SOC, the three most
common adverse events were rash, pruritus,
and urticaria; the 95% CI included zero for all
three of these adverse events.
Adverse Events of Interest
Hypoglycemia
The incidence rates of hypoglycemia were based
on symptomatic reports of hypoglycemia,
regardless of a concurrent glucose
measurement. The predefined analysis for
hypoglycemia (i.e., excluding data after
initiation of glycemic rescue therapy) showed
a between-group difference of -6.2 events per
100 patient-years (95% CI -7.6, -5.0), favoring
the sitagliptin group. The difference observed
for hypoglycemia was mainly due to the use of a
sulfonylurea as a comparator agent in three
studies of up to 2 years in duration, as well as a
study in which patients were switched from
placebo to a sulfonylurea during a double-blind
continuation period (P020 in Table 6 in
Appendix). Results from some individual
studies included in this pooled analysis (in
which sitagliptin was added to either a
sulfonylurea with or without metformin or to
insulin with or without metformin)
demonstrated an increased risk for
hypoglycemia with sitagliptin used in
combination with these agents relative to
placebo. In a separate pooled analysis of
hypoglycemia in which confounding effects of
a sulfonylurea or insulin as either background
or comparator therapies were removed, the
incidence rates of hypoglycemia were 5.6 and
5.1 per 100 patient-years in the sitagliptin
(n = 5,956) and non-exposed (n = 5,122)
groups, respectively, with a between-group
difference of 0.5 events per 100 patient-years
(95% CI -0.7, 1.6).
GI Symptoms
The primary analysis of select GI adverse events
demonstrated similar incidence rates for the
pooled select GI terms, the composite of
abdominal pain terms, nausea, and vomiting
(Table 4). The incidence rate of the adverse
event of constipation was higher in the
sitagliptin group (2.3) than in the non-
exposed group (1.8). For the specific adverse
event of diarrhea, a lower incidence was
observed in the sitagliptin group. The
differences observed for diarrhea mainly
reflected the use of metformin as a
comparator; when the confounding effects of
initiation of metformin were removed, the
incidence rates were 4.3 and 4.9 per 100
patient-years in the sitagliptin (n = 5,940) and
non-exposed (n = 5,122) groups, respectively.
MACE
Detailed description of the analyses of MACE
has been previously published [12]. The
exposure-adjusted incidence of MACE was 0.65
per 100 patient-years in the sitagliptin group,
and 0.74 per 100 patient-years in the non-
exposed group, with an adjusted incidence rate
ratio of 0.83 (95% CI 0.53, 1.30).
Neoplasms
As noted above, the analysis of all events of
malignancies revealed similar incidences in the
two treatment groups: 0.90 per 100 patient
years in the sitagliptin group and 0.93 per 100
patient-years in the non-exposed group
[between-group difference of -0.05 (95% CI
-0.41, 0.30)]. Low incidence rates of a wide
range of specific malignancies were reported,
with similar rates in both treatment groups; the
95% CI did not exclude zero for any of the
specific malignancies that were reported. The
most common malignancies observed were
basal cell carcinoma, prostate cancer, and
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breast cancer (Table 8 in Appendix). Analyses
were performed for the pool of terms
representing the category of pancreatic cancer
(adenocarcinoma of pancreas, pancreatic
carcinoma, pancreatic carcinoma metastatic).
The exposure-adjusted incidence rates for the
pooled terms related to the category of
pancreatic cancer were similar in the two
treatment groups (0.05 and 0.06 events per
100 patient-years in the sitagliptin and non-
exposed groups, respectively). The number of
adverse events (three in each group) was below
the pre-defined threshold for calculating a
95% CI.
The incidence rate of adverse events in the
Neoplasms benign, malignant, and unspecified
SOC overall was 2.03 per 100 patient-years in
the sitagliptin group and 1.52 per 100 patient-
years in the non-exposed group [between-group
difference of 0.52 (95% CI 0.03, 1.01)]. The
higher rate in the sitagliptin group was related
to a higher rate of non-malignant neoplasms in
Table 4 Summary of composite adverse events/adverse events of interest
System organ class Incidence rate per 100 patient-yearsa
Sitagliptin
100 mg
Non-exposed Difference between sitagliptin
and non-exposed (95% CI)b
Acute renal failure (narrow SMQ) 0.2 0.1 0.0 (-0.1, 0.2)
Acute renal failure (broad SMQ) 2.1 1.6 0.4 (-0.1, 0.9)
Atrial ﬁbrillation/ﬂutter 0.4 0.2 0.2 (-0.0, 0.4)
Bronchitis 4.0 3.5 0.5 (-0.2, 1.2)
Gastrointestinal adverse event composite 14.6 15.6 -0.5 (-2.0, 1.0)
Abdominal pain composite 3.7 4.0 -0.3 (-1.1, 0.4)
Constipation 2.3 1.8 0.6 (0.0, 1.1)
Diarrhea 6.6 8.4 -1.4 (-2.5, -0.4)
Nausea 2.8 3.2 -0.2 (-0.9, 0.4)
Vomiting 1.8 1.6 0.3 (-0.2, 0.8)
Pancreatitis 0.1 0.1 -0.0 (-0.2, 0.1)
Pancreatitis (including chronic pancreatitis) 0.1 0.1 0.0 (-0.1, 0.2)
Proteinuria 0.5 0.4 0.1 (-0.2, 0.3)
Pneumonia 0.9 0.8 0.2 (-0.2, 0.5)
Rash 1.7 1.1 0.6 (0.2, 1.1)
Upper respiratory infection 8.2 8.9 -0.6 (-1.7, 0.5)
Urinary tract infection 4.4 4.8 -0.3 (-1.1, 0.4)
SMQ standardized MedDRA queries
a 100 9 (number of patients with C1 event/person years of follow-up time)
b Between-group difference and 95% CI based on stratiﬁed analysis. Positive differences indicate that the incidence rate for
the sitagliptin group is higher than the incidence rate for the non-exposed group. ‘‘0.0’’ and ‘‘-0.0’’ represent rounding for
values that are slightly greater and slightly less than zero, respectively
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the Neoplasms benign, malignant, and
unspecified SOC [incidence rates of 1.18 and
0.60 per 100 patient-years in the sitagliptin and
non-exposed groups, respectively; between-
group difference of 0.60 (95% CI 0.25, 0.96)].
This difference was not the result of an
imbalance in any single adverse event or any
group of biologically related adverse events. The
most common non-malignant neoplasm
adverse event terms observed were uterine
leiomyoma/leiomyoma, lipoma, and skin
papilloma. The only term for which the 95%
CI around the between-group difference
excluded zero was lipoma [between-group
difference 0.15 (95% CI 0.02, 0.29)]. A
sensitivity analysis, performed to assess the
incidence of non-malignant neoplasms across
any SOC, revealed a similar pattern, with
incidences of 1.58 and 1.12 per 100 patient-
years in the sitagliptin and non-exposed groups,
respectively [between-group difference of 0.45
(95% CI 0.02, 0.89)]; in this sensitivity analysis,
the adverse event term ‘‘colonic polyp’’ was the
most common, with similar incidences in the
two treatment groups (0.25 and 0.26 per
100-patient years, respectively).
Angioedema
At baseline, 29.4% and 28.1% of sitagliptin-
treated and non-exposed patients, respectively,
were treated with ACE inhibitors. In the
subgroup defined by ACE inhibitor use, the
exposure-adjusted incidence of events was 0.99
per 100-patient-years in the sitagliptin group
and 1.35 per 100-patient-years in the non-
exposed group; for those patients not treated
with ACE inhibitors, the incidence rates were
1.14 and 1.16, respectively.
Other Composite Endpoints
The following composite endpoints, primarily
of interest due to theoretical mechanistic
concerns and/or post-marketing case reports,
were analyzed.
For the composite endpoint of pancreatitis
(which included the MedDRA terms
‘‘pancreatitis’’ and ‘‘pancreatitis acute’’), the
incidence rates were similar for both groups
(Table 4), with a difference in rate of -0.0 (95%
CI -0.2, 0.1). A similar pattern was observed
with an expanded composite that included the
MedDRA term ‘‘pancreatitis chronic’’.
The incidence of acute renal failure was
assessed using both the narrow SMQ and the
broad SMQ (Table 4); low and similar rates were
observed in both treatment groups for both
composite endpoints, as well as for the
composite endpoint of proteinuria, which
comprised the MedDRA terms ‘‘albumin urine
present’’ or ‘‘protein urine present’’.
Separate analyses were done on the
composite endpoints of bronchitis,
pneumonia, and upper respiratory infection
(Table 4). Similar incidences were seen in both
treatment groups for all three of these infection
composites. Similar incidence rates were also
observed for the composite endpoint of urinary
tract infections (with or without cystitis).
The incidence of the composite endpoint of
rash was higher in the sitagliptin group
compared with the non-exposed group
(Table 4). The difference in the composite
endpoint was primarily related to a higher
incidence of the individual terms ‘‘rash’’ and
‘‘rash macular’’.
The incidence of the individual adverse
event term ‘‘atrial fibrillation’’ was higher in
the sitagliptin group (Table 4). For the
predefined composite endpoint of atrial
fibrillation/atrial flutter, the between-group
difference was 0.2 event per 100 patient-years,
and the 95% CI did not exclude zero (95% CI
-0.0, 0.4).
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Specific Adverse Events for which CI
Excluded Zero
The incidences of adverse events for which the
95% CI excluded zero are depicted in Table 5.
There were 17 specific adverse events in which
the incidence was higher in the sitagliptin
group, and 23 specific adverse events in which
the incidence was higher in the non-exposed
group. For those adverse events in which the
between-group difference was C0.5 events per
100 patient-years, there were two (constipation
and dyspepsia) and seven (diarrhea, fatigue,
edema peripheral, blood glucose decreased,
hypoglycemia, blood glucose increased, and
weight increased) in which the incidences
were higher in the sitagliptin and non-exposed
groups, respectively. Apart from the adverse
event of hypoglycemia, the between-group
differences in adverse events for which the
95% CI excluded zero were all less than 1.5




The proportions of patients in the sitagliptin
and non-exposed groups with their last
measurement (obtained either at the time of
discontinuation or at the final scheduled study
visit) of AST C3 times the upper limit of normal
(ULN) were both 0.3% [between-group
difference 0.0 (95% CI -0.2, 0.2)]; the
proportion of patients whose last ALT
measurement was C3 times the ULN were
0.8% and 0.6%, respectively [between-group
difference 0.0 (95% CI -0.0, 0.5)]. One patient
in each group had a last value of ALT or AST C3
times the ULN with a simultaneous elevation of
the total serum bilirubin C2 times the ULN.
Serum Creatinine
Similar proportions of patients had a last
measurement of serum creatinine with an
increase of C0.3 mg/dL (1.8% and 1.7% in the
sitagliptin and the non-exposed groups,
respectively). The proportions of patients who
met the predefined criterion of two or more
consecutive serum creatinine measurements
with an increase from baseline of C0.3 mg/dL,
or an increase from baseline of C50% were also
similar in the two groups (0.8% and 0.6%,
respectively).
DISCUSSION
An increase in the number of classes of
antihyperglycemic therapy options available
for the treatment of patients with type 2
diabetes offers patients more choices of
effective and well-tolerated therapies that are
needed for management of this chronic disease.
Assessment of the risk/benefit profile of each
class, and specific agents within each class,
determines their value for patient
management, and this has been acknowledged
by the continued evolution of treatment
guidelines [1]. Selective DPP-4 inhibitors,
which provide physiologic increases in the
incretins GLP-1 and gastric inhibitory
polypeptide (GIP), offer the potential to be a
preferred option for the management of
hyperglycemia, since they lack many of the
adverse effects observed with other diabetes
medications (e.g., hypoglycemia, weight gain)
[13]. Nevertheless, continued assessment of the
safety and tolerability profile of newer agents,
including DPP-4 inhibitors, is necessary as more
patients are exposed to such treatments, both
through expanded analyses of controlled
clinical trial data as well as ongoing
pharmacovigilance activities. While
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Table 5 Adverse events for which the 95% conﬁdence intervals around the difference in incidence rates excludes zero
Adverse event Incidence rate per 100 patient-yearsa
Sitagliptin 100 mg Non-exposed Difference between sitagliptin
and non-exposed (95% CI)b
Sitagliptin[non-exposed
Acne 0.2 0.0 0.1 (0.0, 0.3)
Atrial ﬁbrillationc 0.4 0.2 0.2 (0.0, 0.4)
Chest discomfort 0.3 0.1 0.2 (0.0, 0.4)
Constipation 2.3 1.8 0.6 (0.0, 1.1)
Dermatitis contact 0.6 0.3 0.3 (0.0, 0.6)
Dyspepsia 2.0 1.4 0.6 (0.0, 1.1)
Gilbert’s syndrome 0.1 0.0 0.1 (0.0, 0.2)
Hepatomegaly 0.1 0.0 0.1 (0.0, 0.3)
Ischemic cardiomyopathy 0.1 0.0 0.1 (0.0, 0.2)
Lipoma 0.2 0.0 0.1 (0.0, 0.3)
Micturition urgency 0.1 0.0 0.1 (0.0, 0.2)
Ovarian cyst 0.1 0.0 0.1 (0.0, 0.2)
Periodontitis 0.3 0.1 0.2 (0.0, 0.3)
Rash macular 0.2 0.0 0.1 (0.0, 0.3)
Rash vesicular 0.1 0.0 0.1 (0.0, 0.2)
Tibia fracture 0.1 0.0 0.1 (0.0, 0.2)
Vaginal hemorrhage 0.1 0.0 0.1 (0.0, 0.2)
Non-exposed[sitagliptin
Albumin urine present 0.0 0.2 -0.1 (-0.3, -0.0)
Blood glucose decreased 0.7 1.3 -0.5 (-0.9, -0.1)
Blood glucose increased 2.0 3.1 -1.1 (-1.8, -0.6)
Blood triglycerides increased 0.5 0.7 -0.3 (-0.6, -0.0)
Bradycardia 0.0 0.2 -0.2 (-0.3, -0.1)
Diarrhea 6.6 8.4 -1.4 (-2.5, -0.4)
Fatigue 1.6 2.1 -0.5 (-1.1, -0.0)
Hypoglycemia 6.7 13.0 -6.3 (-7.6, -5.1)
Hypoesthesia 0.7 1.0 -0.4 (-0.7, -0.0)
Neck pain 0.6 0.9 -0.3 (-0.7, -0.0)
Neurodermatitis 0.0 0.1 -0.1 (-0.2, -0.0)
Peripheral edema 2.2 3.0 -0.8 (-1.4, -0.2)
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pharmacovigilance activities, which include
assessment of post-marketing adverse event
reports, are of value in identifying potential
safety signals, it is well-recognized that these
voluntary, spontaneous adverse event reports
are derived from a population of uncertain size;
thus, it is generally not possible to reliably
establish the incidence of such events or to
establish a causal relationship between a
medication and a specific adverse event.
Assessment of the incidence of adverse events
from randomized, controlled, clinical trials
remains the gold standard for rigorous
evaluation of potential safety issues.
Prior pooled analyses of randomized,
controlled, clinical trials with sitagliptin, the
first-marketed DPP-4 inhibitor, indicated that
this agent was generally well tolerated in studies
up to 2 years in duration. These data were
generally consistent with subsequent pooled
analyses of other DPP-4 inhibitors using
patient-level data [14–16] as well as with meta-
analyses of the DPP-4 class using study-level
data [3, 17, 18].
In this current report, the safety and
tolerability of sitagliptin was assessed in an
expanded pool of studies that comprised over
14,000 patients, representing the largest
Table 5 continued
Adverse event Incidence rate per 100 patient-yearsa
Sitagliptin 100 mg Non-exposed Difference between sitagliptin
and non-exposed (95% CI)b
Pharyngeal erythema 0.0 0.1 -0.1 (-0.2, -0.0)
Sepsis 0.0 0.1 -0.1 (-0.2, -0.0)
Sinus headache 0.1 0.3 -0.2 (-0.4, -0.1)
Suicidal ideation 0.0 0.1 -0.1 (-0.2, -0.0)
Thrombophlebitis 0.0 0.2 -0.1 (-0.3, -0.0)
Urine ketone body present 0.0 0.1 -0.1 (-0.3, -0.0)
Weight increased 0.8 1.4 -0.6 (-1.0, -0.2)
White blood cell count increased 0.1 0.3 -0.2 (-0.4, -0.0)
Upper airway cough syndrome 0.0 0.1 -0.1 (-0.3, -0.0)
Vitreous detachment 0.0 0.1 -0.1 (-0.2, -0.0)
Wheezing 0.0 0.1 -0.1 (-0.3, -0.0)
a 100 9 (number of patients with C1 event/patient-years of follow-up time)
b Between-group difference and 95% CI based on stratiﬁed analysis. Positive differences indicate that the incidence rate for
the sitagliptin group is higher than the incidence rate for the non-exposed group. ‘‘0.0’’ and ‘‘-0.0’’ represent rounding for
values that are slightly greater and slightly less than zero, respectively
c When atrial ﬁbrillation and atrial ﬂutter were combined, the between-group difference was 0.2 (95% CI -0.0, 0.4).
Incidence rates for atrial ﬂutter were 0.0 and 0.1 for the sitagliptin and the non-exposed groups, respectively, with a between-
group difference of -0.1 (95% CI -0.2, 0.0)
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patient-level data set published to date for a
DPP-4 inhibitor. This updated analysis, which
expanded on the prior analysis by the addition
of six clinical trials, 4,365 patients and 3,114
patient-years of exposure, revealed that
treatment with sitagliptin was generally well
tolerated, with exposure-adjusted incidence
rates of adverse events generally similar to
those observed with control therapy that did
not include sitagliptin or other DPP-4 inhibitor.
The attainment of currently recommended
glycemic goals is limited, in large part, by the
increased incidence of hypoglycemia seen with
intensive therapies, and particularly with
glucose-independent regimens, which include
sulfonylureas and insulin. Incretin-based
therapies, which provide a glucose-dependent
mechanism for enhanced insulin secretion and
reduced glucagon secretion, should
theoretically be devoid of this risk. Consistent
with this mechanistic consideration, the
analysis of symptomatic hypoglycemia in
studies in which sitagliptin was used as
monotherapy or combination therapy (where
there was no use of sulfonylureas or insulin)
revealed similar rates of symptomatic
hypoglycemia for sitagliptin-treated patients
compared with non-exposed patients (who
received either placebo, metformin, or
pioglitazone as comparator agents). The
incidence of symptomatic hypoglycemia was
lower in the pooled sitagliptin-treated
population, mainly related to the use of
sulfonylureas as a comparator in several
studies. As reported in several clinical trials,
the addition of sitagliptin to regimens
containing sulfonylurea or insulin resulted in
an expected increase in the incidence of
symptomatic hypoglycemia related to
improvements in glycemic control and a
general lowering of ambient glucose
concentrations [19, 20]. These findings are
consistent with those seen with other classes
of antihyperglycemic agents that do not cause
hypoglycemia when used as monotherapy, but
do so when added onto sulfonylureas or insulin
[21, 22]. Thus, in the context of combinations
of antihyperglycemic therapies, the risk
of hypoglycemia should be carefully
considered in choosing appropriate treatment
combinations.
An increase in the incidence of GI symptoms
is characteristic of treatment with GLP-1
receptor agonists and with metformin. In the
current pooled analysis, similar exposure-
adjusted incidences were seen in both
treatment groups for nausea, vomiting, a
composite endpoint of terms related to
abdominal pain, and a composite of diverse GI
adverse events. Consistent with earlier pooled
analyses [5, 6], there was a lower incidence of
diarrhea and a higher incidence of constipation
observed in the sitagliptin treatment group.
These findings were, in part, related to the
known effects of metformin on increasing the
incidence of diarrhea. However, in a sensitivity
analysis in which the confounding effects of
metformin as a comparator was removed, a
modest increase in the incidence of
constipation was still observed. The
mechanism underlying this observation is not
understood; while DPP-4 inhibitors have not
been observed to slow gastric emptying, it
remains possible that the physiologic
elevations in GLP-1 may have an impact on
intestinal motility.
Interest in the relationship between
antihyperglycemic agents and pancreatitis was
triggered originally by post-marketing reports of
acute pancreatitis in patients with type 2
diabetes treated with exenatide [23, 24]. Post-
marketing reports of acute pancreatitis in
patients treated with all currently marketed
GLP-1 mimetics and DPP-4 inhibitors have
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been observed, and are noted in the labeled
information for these products, including
sitagliptin [25]. Post-marketing reports
represent voluntary, spontaneous adverse
event reports regardless of etiology or
probability that the medication caused the
adverse event. Additionally, post-marketing
events are reported from a population of
uncertain size; thus, it is generally not possible
to reliably establish the frequency of such
events or to establish a causal relationship
between a medication and a specific adverse
event. As noted by the US Food and Drugs
Administration (FDA), spontaneous reports
such as those contained in the FDA’s Adverse
Event Reporting System (AERS) database cannot
be used to calculate the incidence of an adverse
event [26]. Thus, an analysis of the AERS
database that revealed an increase in the
reporting rates for pancreatitis with sitagliptin
and with exenatide is difficult to interpret, in
part due to these intrinsic methodological
limitations [27]. In a recently published
analysis using a case–control study design,
Singh et al. [28] reported a higher rate of
hospitalizations for acute pancreatitis in
patients with type 2 diabetes associated with
the use of incretin-based therapies (sitagliptin
or exenatide). This analysis has a number of
methodological limitations, including the
absence of data on pre-disposing baseline
characteristics to allow for robust adjustment
for confounding factors, a lack of confirmation
of the diagnostic codes used, and lack of
adjustment for potential channeling bias [29],
which could result in preferential prescribing of
incretin-based therapies to patients who were at
greater risk for pancreatitis prior to treatment
due to age, obesity or other risk factors.
Randomized, controlled clinical trial data
provide a more robust assessment of the
incidence of adverse events. In the current
pooled analysis, the incidence of acute
pancreatitis was similar in the sitagliptin-
treated and the non-exposed group, with
exposure-adjusted incidence rates of 0.1 and
0.1 events per 100 patient-years, respectively.
Similar findings were observed in the analysis of
the composite endpoint of acute and chronic
pancreatitis. These data are consistent with
those reported previously in a smaller pooled
analysis [4], and are also consistent with
the systematic pharmacoepidemiologic
retrospective cohort assessments performed in
two large insurance claims databases [30, 31].
Events of pancreatitis will also be assessed in the
sitagliptin cardiovascular outcome study TECOS
[32], in which over 14,000 patients are currently
enrolled; all cases of pancreatitis will be
investigated by an adjudication committee
(blinded to treatment assignment) using
standard criteria for confirmation of the
diagnosis of pancreatitis.
The relationship between antihyperglycemic
therapies and malignancy has recently been a
focus of increased attention. This is of particular
importance in view of the reported association
between both obesity and diabetes with an
increased risk of malignancy [33], and recent
associations of pioglitazone with bladder cancer
[34], and dapagliflozin with bladder and breast
cancer [35]. In the current pooled analysis, the
exposure-adjusted incidence of malignancy was
similar for sitagliptin-treated patients and non-
exposed patients. The most common
malignancies observed (basal cell carcinoma,
prostate cancer and breast cancer) were
reflective of the demographics of the
population, and the incidence rates for these
malignancies were similar in patients treated
with sitagliptin and those not treated with
sitagliptin. Of additional note was the similar
incidence of pancreatic cancer in the two
treatment groups. The relatively short-term
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duration of exposure (B2 years) precludes
definitive conclusions regarding any potential
association with malignancy, but the lack of
any signal in this randomized, controlled,
clinical trial database is reassuring.
Additionally, the incidence of cancer will be
assessed in the long-term cardiovascular
outcome study TECOS [32], in which a median
duration of follow-up of 4 years is anticipated.
As had been observed in a previous pooled
analysis [6], there was a slightly higher
incidence of non-malignant neoplasms in the
sitagliptin treatment group compared with the
non-exposed group (1.18 versus 0.60 events
per 100 patient-years). The between-group
difference in incidence rates did not exclude
zero for any non-malignant neoplasm other
than lipoma. The most commonly observed
non-malignant neoplasms (i.e., colonic polyp,
uterine leiomyoma, and lipoma) were
reflective of the expected pattern in the
general adult population [36–38], and
included a collection of disparate and diverse
types of lesions of varying histology and
biology. The large number of unrelated
adverse event terms assessed in these pooled
analyses and the varying and diverse
histologies that underlie the reported non-
malignant neoplasms suggest that the small
increase in the incidence rate of non-
malignant neoplasms in the sitagliptin group
relative to the non-exposed group may be a
stochastic finding and not related to the use
of sitagliptin.
The incidence rate ratio of MACE in this
pooled analysis was 0.83 (95% CI 0.53, 1.30). It
is of interest that both preclinical and clinical
mechanistic studies have demonstrated benefits
of incretin-based therapies on cardiovascular
function and outcomes [39, 40]. These data
from the pooled analysis are consistent with a
potential beneficial effect of sitagliptin on
cardiovascular outcomes, but definitive
evaluation of the cardiovascular effects of
sitagliptin awaits the completion of the TECOS
trial.
Over 17% of patients with diabetes are
reported to have chronic kidney disease, and
diabetes is associated with progressive renal
insufficiency [41]. Clinical trials of sitagliptin
in patients with moderate and severe renal
insufficiency have indicated that sitagliptin is
generally well tolerated in this population [7–
9]. In this current pooled analysis of patients
with normal or mildly impaired renal function,
the evaluation of the impact of sitagliptin on
renal function included an assessment of
predefined changes in serum creatinine, and
the incidence of adverse events related to
progressive renal dysfunction (proteinuria and
acute renal failure). For all of these measures,
no difference between the two treatment
groups was observed for the proportion of
patients reaching the predefined laboratory
abnormality thresholds or in the incidence of
adverse events of proteinuria or acute renal
failure.
The following are limitations of the present
pooled analysis: the results are from patients
included in randomized, controlled clinical
studies of up to years in duration and, thus,
may not be fully reflective of the use in the
general population, nor of more prolonged use;
the analysis focused on sitagliptin 100 mg/day,
the usual clinical dose; and there were multiple
comparisons made without an adjustment for
multiplicity, which increased the chances for
spurious findings. The strengths of these
analyses include the ability to account for all
reported adverse events using patient-level data,
and the large number of clinical trials and
patients analyzed.
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CONCLUSION
In this updated pooled safety analysis based on
data available as of December 2011 from over
14,000 patients with type 2 diabetes, treatment
with sitagliptin 100 mg/day was generally well
tolerated as monotherapy, as initial
combination therapy, and as add-on therapy
in double-blind, randomized clinical studies of
up to 2 years in duration. Continued assessment
of adverse events reported from clinical trials
and from the post-marketing environment is
ongoing.
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Table 7 Adverse events with at least 1 incident event per 100 patient-years in one or both groups
Adverse event Incidence rate per 100 patient-yearsa
Sitagliptin 100 mg Non-exposed Difference between sitagliptin
and non-exposed (95% CI)b
Gastrointestinal disorders SOC
Abdominal painc 3.7 4.0 -0.3 (-1.1, 0.4)
Constipation 2.3 1.8 0.6 (0.0, 1.1)
Diarrhea 6.6 8.4 -1.4 (-2.5, -0.4)
Dyspepsia 2.0 1.4 0.6 (0.0, 1.1)
Gastritis 1.4 1.4 0.0 (-0.4, 0.4)
Gastroesophageal reﬂux disease 1.0 0.7 0.3 (-0.0, 0.7)
Nausea 2.8 3.2 -0.2 (-0.9, 0.4)
Toothache 1.1 1.3 -0.3 (-0.7, 0.1)
Vomiting 1.8 1.6 0.3 (-0.2, 0.8)
General disorders and administration site conditions SOC
Fatigue 1.6 2.1 -0.5 (-1.1, -0.0)
Peripheral edema 2.2 3.0 -0.8 (-1.4, -0.2)
Infections and infestations SOC
Bronchitis 3.7 3.3 0.5 (-0.2, 1.1)
Gastroenteritis 2.1 1.6 0.5 (-0.0, 1.0)
Inﬂuenza 4.0 4.7 -0.7 (-1.5, 0.0)
Nasopharyngitis 7.3 7.1 0.4 (-0.6, 1.4)
Pharyngitis 1.7 1.6 0.0 (-0.5, 0.5)
Sinusitis 2.3 2.4 -0.0 (-0.6, 0.5)
Upper respiratory tract infection 7.8 8.4 -0.5 (-1.6, 0.6)
Urinary tract infection 3.9 4.2 -0.3 (-1.1, 0.4)
Investigations SOC
ALT increased 1.5 1.3 0.2 (-0.2, 0.7)
Blood glucose decreased 0.7 1.3 -0.5 (-0.9, -0.1)
Blood glucose increased 2.0 3.1 -1.1 (-1.8, -0.6)
Weight increased 0.8 1.4 -0.6 (-1.0, -0.2)
Metabolism and nutrition disorders SOC
Hyperglycemia 1.4 1.6 -0.3 (-0.8, 0.2)
Hypoglycemia 6.7 13.0 -6.3 (-7.6, -5.1)
Musculoskeletal and connective tissue disorders SOC
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Table 7 continued
Adverse event Incidence rate per 100 patient-yearsa
Sitagliptin 100 mg Non-exposed Difference between sitagliptin
and non-exposed (95% CI)b
Arthralgia 3.3 3.6 -0.3 (-1.0, 0.4)
Back pain 4.2 3.9 0.2 (-0.5, 1.0)
Muscle spasms 1.1 1.3 -0.2 (-0.6, 0.2)
Musculoskeletal pain 1.5 1.5 -0.1 (-0.5, 0.4)
Myalgia 1.1 1.2 -0.1 (-0.5, 0.3)
Osteoarthritis 1.4 1.1 0.2 (-0.2, 0.6)
Pain in extremity 2.6 2.1 0.5 (-0.1, 1.0)
Nervous system disorders SOC
Dizziness 2.6 2.6 -0.0 (-0.6, 0.6)
Headache 5.8 5.4 0.5 (-0.3, 1.4)
Hypoesthesia 0.7 1.0 -0.4 (-0.7, -0.0)
Paraesthesia 1.1 1.1 -0.1 (-0.5, 0.3)
Psychiatric disorders SOC
Depression 1.3 1.2 0.2 (-0.2, 0.6)
Insomnia 1.4 1.3 0.1 (-0.4, 0.5)
Respiratory, thoracic, and mediastinal disorders SOC
Cough 2.5 2.4 0.0 (-0.6, 0.6)
Oropharyngeal pain 1.2 1.1 0.1 (-0.3, 0.5)
Skin and subcutaneous tissue disorders SOC
Rash 1.2 0.9 0.3 (-0.1, 0.7)
Vascular disorders SOC
Hypertension 3.4 3.4 -0.1 (-0.8, 0.6)
ALT alanine aminotransferase, SOC system organ class
a 100 9 (number of patients with C1 event/patient-years of follow-up time)
b Between-group difference and 95% CI based on stratiﬁed analysis. Positive differences indicate that the incidence rate for
the sitagliptin group is higher than the incidence rate for the non-exposed group. ‘‘0.0’’ and ‘‘-0.0’’ represent rounding for
values that are slightly greater and slightly less than zero, respectively
c Abdominal pain includes abdominal pain, upper and lower abdominal pain, and abdominal and epigastric discomfort
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Table 8 Analysis of malignant neoplasms
Malignant neoplasm Incidence rate per 100 patient-yearsa
Sitagliptin 100 mg Non-exposed Difference between sitagliptin
and non-exposed (95% CI)b
Adenocarcinoma pancreas 0.00 0.02 -0.02
Astrocytoma malignant 0.00 0.04 -0.04
B-cell lymphoma 0.02 0.00 0.01
Basal cell carcinoma 0.14 0.19 -0.05 (-0.22, 0.11)
Bladder cancer 0.03 0.02 0.01
Bladder transitional cell carcinoma 0.02 0.00 0.02
Breast cancer 0.09 0.07 0.02 (-0.11, 0.15)
Carcinoid tumour of the small bowel 0.00 0.02 -0.02
Colon cancer 0.09 0.04 0.06 (-0.06, 0.19)
Diffuse large B-cell lymphoma 0.02 0.00 0.02
Endometrial cancer metastatic 0.00 0.02 -0.02
Fallopian tube cancer 0.00 0.02 -0.01
Gastric cancer 0.02 0.00 0.02
Glioblastoma multiforme 0.00 0.02 -0.02
Hepatic neoplasm malignant 0.02 0.02 -0.01
Hepatic neoplasm malignant non-resectable 0.00 0.02 -0.02
Laryngeal cancer 0.02 0.00 0.02
Lip and/or oral cavity cancer 0.02 0.00 0.02
Lung adenocarcinoma metastatic 0.00 0.02 -0.02
Lung carcinoma cell type unspeciﬁed stage IV 0.02 0.00 0.02
Lung neoplasm malignant 0.00 0.04 -0.04
Lung squamous cell carcinoma stage unspeciﬁed 0.02 0.00 0.02
Lymphoma 0.00 0.02 -0.02
Malignant melanoma 0.05 0.07 -0.02 (-0.14, 0.09)
Metastases to bone 0.03 0.02 0.01
Metastatic renal cell carcinoma 0.02 0.00 0.02
Myelodysplastic syndrome 0.00 0.02 -0.02
Non-small cell lung cancer 0.02 0.00 0.02
Oesophageal adenocarcinoma 0.00 0.02 -0.02
Oesophageal cancer metastatic 0.00 0.02 -0.02
Ovarian epithelial cancer 0.02 0.00 0.01
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